Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis

Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Key Stats

• Today's Range: $15.61 to $15.87
• 50-Day Range: $13.26 to $16.89
• 52-Week Range: $8.03 to $17.75
• Volume: 568,833 shs
• Average Volume: 2.11 million shs
• Market Capitalization: $1.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.80
• Consensus Rating: Moderate Buy

Arcutis Biotherapeutics Stock Analysis - MarketRank™

Arcutis Biotherapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 725th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Arcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($1.33) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcutis Biotherapeutics is -20.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcutis Biotherapeutics is -20.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcutis Biotherapeutics has a P/B Ratio of 11.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.32% of the float of Arcutis Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Arcutis Biotherapeutics has recently decreased by 3.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcutis Biotherapeutics does not currently pay a dividend.

Dividend Growth

Arcutis Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.32% of the float of Arcutis Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.9.

Change versus previous month

Short interest in Arcutis Biotherapeutics has recently decreased by 3.65%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.06

News Sentiment

Arcutis Biotherapeutics has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.

Search Interest

Only 5 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

MarketBeat Follows

6 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcutis Biotherapeutics insiders have sold 1,675.41% more of their company's stock than they have bought. Specifically, they have bought $64,853.00 in company stock and sold $1,151,404.00 in company stock.

Percentage Held by Insiders

Only 9.40% of the stock of Arcutis Biotherapeutics is held by insiders.

ARQT Stock Analysis - Frequently Asked Questions

How have ARQT shares performed this year?

Arcutis Biotherapeutics' stock was trading at $13.93 at the start of the year. Since then, ARQT stock has increased by 12.8% and is now trading at $15.71.

How were Arcutis Biotherapeutics' earnings last quarter?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its earnings results on Wednesday, August, 6th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. The firm earned $81.50 million during the quarter, compared to the consensus estimate of $72.70 million. Arcutis Biotherapeutics had a negative net margin of 35.40% and a negative trailing twelve-month return on equity of 62.62%.
Read the conference call transcript.

When did Arcutis Biotherapeutics IPO?

Arcutis Biotherapeutics (ARQT) raised $125 million in an initial public offering (IPO) on Friday, January 31st 2020. The company issued 7,800,000 shares at $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager.

Who are Arcutis Biotherapeutics' major shareholders?

Top institutional investors of Arcutis Biotherapeutics include Jennison Associates LLC (9.32%), Rubric Capital Management LP (8.97%), Frazier Life Sciences Management L.P. (8.24%) and State Street Corp (3.78%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Masaru Matsuda, Larry Todd Edwards, David Joseph Topper, Patrick Burnett, Howard G Welgus, Latha Vairavan, Patricia A Turney, Scott L Burrows, Patrick J Heron and Terrie Curran.
View institutional ownership trends.

How do I buy shares of Arcutis Biotherapeutics?

Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Arcutis Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/26/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARQT
• CIK: 1787306
• Web: www.arcutis.com
• Phone: 805-418-5006
• Fax: N/A
• Employees: 150
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Arcutis Biotherapeutics: $19.80
• High Price Target: $22.00
• Low Price Target: $18.00
• Potential Upside/Downside: +26.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$140.04 million
• Net Margins: -35.40%
• Pretax Margin: -35.04%
• Return on Equity: -62.62%
• Return on Assets: -25.16%

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 3.20
• Quick Ratio: 3.04

Sales & Book Value

• Annual Sales: $263.47 million
• Price / Sales: 7.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.35 per share
• Price / Book: 11.62

Miscellaneous

• Outstanding Shares: 119,905,000
• Free Float: 108,634,000
• Market Cap: $1.88 billion
• Optionable: Optionable
• Beta: 1.84